PDCD1 and head and neck squamous cell carcinoma: Extensive clinical data demonstrate that neoadjuvant treatment combining PD-1 inhibitors with paclitaxel and cisplatin exhibits favorable efficacy and tolerability for laryngeal preservation therapy in locally advanced HNSCC.